Mizuho Securities Downgrades Atara Biotherapeutics to Neutral From Buy, Slashes Price Target to $1 From $31
Mizuho Securities Downgrades Atara Biotherapeutics to Neutral From Buy, Slashes Price Target to $1 From $31
瑞穗证券将Atara Biotherapeutics的评级从买入下调至中性，将目标股价从31美元下调至1美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册